Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $531.14 MXN
Change Today +9.64 / 1.85%
Volume 60.9K
PFE* On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 4:09 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE*) Snapshot

Open
$532.50
Previous Close
$521.50
Day High
$532.50
Day Low
$526.86
52 Week High
04/24/15 - $544.66
52 Week Low
08/12/14 - $369.18
Market Cap
3.3T
Average Volume 10 Days
22.0K
EPS TTM
--
Shares Outstanding
6.1B
EX-Date
05/6/15
P/E TM
--
Dividend
$1.12
Dividend Yield
2.73%
Current Stock Chart for PFIZER INC (PFE*)

pfizer inc (PFE*) Details

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has collaboration with BIND Therapeutics, Inc. to develop and commercialize multiple Accurins. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

78,300 Employees
Last Reported Date: 02/27/15
Founded in 1849

pfizer inc (PFE*) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.3M
President of Worldwide Research & Development
Total Annual Compensation: $1.2M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $1.2M
Group President of Global Established Pharma ...
Total Annual Compensation: $1.0M
Compensation as of Fiscal Year 2014.

pfizer inc (PFE*) Key Developments

Pfizer Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 29, 2015; Revises Earnings Guidance for the Full Year 2015

Pfizer Inc. reported unaudited consolidated earnings results for the first quarter ended March 29, 2015. For the quarter, the company reported revenues of USD 10,864 million against USD 11,353 million for the same quarter a year ago. Income from continuing operations before provision for taxes on income was USD 3,082 million against USD 2,847 million for the same quarter a year ago. Income from continuing operation was USD 2,376 million or USD 0.38 per basic and diluted share against USD 2,265 million or USD 0.35 per basic and diluted share for the same quarter a year ago. Net income attributable to company was USD 2,376 million or USD 0.38 per basic and diluted share against USD 2,329 million or USD 0.36 per basic and diluted share for the same quarter a year ago. Adjusted income from continuing operations before provision for taxes on income was USD 4,235 million against USD 4,901 million a year ago. Adjusted income from continuing operations was USD 3,201 million against USD 3,674 million a year ago. Adjusted net income attributable to company was USD 3,196 million or USD 0.51 per diluted share against USD 3,665 million or USD 0.57 per diluted share a year ago. The company revised earnings guidance for the year 2015. For the year, the company expects reported revenues to be in the range of USD 44.0 million to USD 46.0 million compared to previous guidance range of USD 44.5 million to USD 46.5 million, effective tax rate on adjusted income of approximately 25.0%, reported diluted EPS to be in the range of USD 1.32 to 1.47 compared to previous guidance range of USD 1.37 to USD 1.52 and adjusted diluted EPS to be in the range of USD 1.95 to 2.05 compared to previous guidance range of USD 2.00 to USD 2.10. The company expects adjusted income to be in the range of USD 12.2 billion to USD 12.8 billion and reported net income attributable to company to be in the range of USD 8.3 billion to USD 9.2 billion.

Pfizer Mulls Acquisitions

Pfizer Inc. (NYSE:PFE) intends to make acquisitions. Ian Read Chairman and Chief Executive Officer of the company said: “On the Consumer business, it actually had a very good quarter, very good growth. So, it's a business that we like to be in. I think it's a strategically important business for us. And we will continue to develop it. And if we have opportunities to do acquisitions to grow it, we'll also look at those. So, it's a good business to be in.”

Swedish Orphan Biovitrum Reportedly Open To Takeover Offers

Swedish Orphan Biovitrum AB (OM:SOBI) is open to potential takeover offers after its stock reached an all-time high, Bloomberg reported, citing people familiar with the matter. The company, also known as Sobi, has held on and off talks with potential buyers since last year. Interested parties include Pfizer Inc. (NYSE:PFE), which has an existing partnership with the company, and Biogen Inc. (NasdaqGS:BIIB), Bloomberg said, citing people familiar with the matter.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE*:MM $531.14 MXN +9.64

PFE* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $105.66 USD +0.65
Merck & Co Inc $60.64 USD +0.78
Nestle SA SFr.73.00 CHF 0.00
Roche Holding AG SFr.271.30 CHF +2.30
Procter & Gamble Co/The $80.35 USD +0.06
View Industry Companies
 

Industry Analysis

PFE*

Industry Average

Valuation PFE* Industry Range
Price/Earnings 23.6x
Price/Sales 4.3x
Price/Book 3.0x
Price/Cash Flow 16.0x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.